genomeweb | By John Gilmore, January 17, 2019

NEW YORK (GenomeWeb) – Fresh off being awarded several grants by the National Institutes of Health, startup BioFluidica has begun three different clinical studies to detect exosomes, cell-free DNA, and rare cells in patients’ bloodstreams to identify acute lymphoblastic leukemia (ALL) and other cancer-related diseases.

The San Diego, California-based startup is also exploring the use of its Liquid Scan platform in the non-invasive prenatal testing space by extracting and detecting neonatal cells from a mother’s bloodstream.

PDF Download